Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · IN8BIO, INC. (INAB)

IN8bio Q3 2026 net loss widens to $4.6 million from $3.9 million

Negative Impact 3 of 5 earnings Written later

IN8bio reported third quarter 2026 results on November 5, 2026. The net loss widened to $4.6 million from $3.9 million a year earlier, as research and development expenses rose to $2.6 million from $2.1 million, mainly due to preclinical costs for its T cell engager platform. Cash was $14.0 million at September 30, 2026, down from $27.1 million at December 31, 2025, and the company has no revenue reported in the filing, so shareholders face a higher loss and a shrinking cash balance.

Key points

  • Net loss of $4.6 million, or $0.24 per share, versus $3.9 million, or $0.85 per share, a year earlier
  • R&D expenses of $2.6 million versus $2.1 million, driven mainly by preclinical T cell engager costs
  • Cash of $14.0 million at September 30, 2026, versus $10.7 million a year earlier and $27.1 million at December 31, 2025
  • Company remains on track to report initial in vivo preclinical data for INB-619 by year-end 2026

The filing

CompanyIN8BIO, INC. (INAB)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:10 PM ET
Accession number0001193125-26-449820

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.